Next Generation Sequencer

描述(由申请人提供)：这项共享仪器拨款申请中的拟议工作来自于俄亥俄州东北部地区的一家主要研究机构克利夫兰诊所正在进行的许多临床和/或转化性研究项目。这项申请的目的是寻求资金购买下一代测序仪，Illumina基因组分析仪IIx。除一人外，所有主要用户都是由各种机制(R01、P01、U54等)资助的NIH/NCI。基因组分析仪具有强大的功能和灵活性，可以实现广泛的基因组规模的应用。该仪器是美国国立卫生研究院1000美元基因组计划的直接结果，代表了进入市场的第一代此类技术。基本技术可以概括为大规模并行测序(在典型的3-5天运行中创建2-4 GB的序列)。根据申请的详细情况，所支持的项目主要包括生物标记物发现和临床/翻译科学研究，它们代表了我们机构的独特优势，并利用了下一代测序仪目前的所有应用：1)数字基因表达谱：比基于微阵列的谱图更好的动态范围和对低丰度转录本的可靠检测；2)芯片序列：DNA-蛋白质相互作用的全基因组图谱，以及与人类疾病相关的翻译研究计划中的表观遗传调控；3)小分子或非编码RNA的发现；4)基因组测序：对患者DNA中的大基因组区域进行重新测序，以发现致病突变。收购基因组分析仪及其规模和价值，对于将目前由NIH资助的项目和许多其他新项目提升到俄亥俄州东北部更高水平的翻译科学至关重要。克利夫兰诊所已经为翻译基因组学和基因组医学的发展投入了大量资源，包括建立其基因组医学研究所，建立一个新的基因组核心设施，配备监督运营的人员，以及确保其长期运营和维护的财务计划。

DESCRIPTION (provided by applicant): The proposed work in this shared instrumentation grant application comes from many of the clinical and/or translational research programs ongoing at the Cleveland Clinic, a major research institution in the northeast Ohio region. The purpose of this application is to seek funding to purchase a next generation sequencer, the Illumina Genome Analyzer IIx. All but one of the major users is NIH/NCI funded by a variety of mechanisms (R01, P01, U54, etc). The Genome Analyzer has the power and flexibility to enable a wide range of genome-scale applications. The instrument is a direct consequence of the NIH initiative for the $1000 genome and represents the first generation of such technologies to come to the market. The underlying technology can be summarized as massive parallel sequencing (creating 2-4 GB of sequence in a typical 3-5 day run). As detailed in the application, the supported projects primarily include biomarker discovery and clinical/translational sciences studies, representing the unique strengths in our institution and taking advantage of all current applications of the next generation sequencers: 1) digital gene expression profiling: better dynamic range than micro-array based profiling and reliable detection of low-abundance transcripts, 2) ChIP-seq: genome wide profiles of DNA-protein interaction and of epigenetic regulation in translational research programs related to human disease, 3) small or non-coding RNA discovery and 4) genome sequencing: re- sequencing of large genomic regions in patient DNA to uncover disease causing mutations. The acquisition of the Genome Analyzer, with its scale and value, are essential in lifting the currently NIH-funded projects and many other new projects to the next higher level of translational sciences in northeast Ohio. Cleveland Clinic has already committed substantial resources to the development of translational genomics and genomic medicine, including the founding of its Genomic Medicine Institute with a new Genomics Core Facility, personnel to oversee operations and a fiscal plan to ensure its operation and maintenance for the long-term.